Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
RXRX Recursion Pharmaceuticals posts narrowerthanexpected Q1 2026 loss shares climb 178 on positive investor sentiment Why John Wiley WLY financial health is stronger than most think Ticks Lower 20260506 NOVT Novanta posts narrow Q4 2025 EPS beat with shares falling over 6 percent in todays trading session What favorite stocks Hims HIMS Declines 20260429 Train Blast in Quetta Injures Dozens Raises Security Concerns for Pakistans Transport Sector Analysts Eye April Jobs Report as Labor Market Shows Signs of Slowing Indian Market Ends Week on Positive Note LowPriced Stocks Draw Attention Tokyo Governor Pushes Hydrogen and AI Collaboration as Model for Resilient Urban Economies Chinese Drone Shipments Face Significant Decline Amid Domestic Regulations and US Import Ban Japan Identified as Part of Fentanyl Smuggling Route by US Official Raising Economic and Security Concerns HAYW Q1 2026 Earnings EPS Surpasses Estimates by 1414 as Stock Declines Slightly ZTO Q1 2026 Earnings Strong EPS Reported Amid Limited Disclosures Willdan Group Q1 2026 Earnings EPS Beat Drives 32 Stock Gain TD Q1 2026 Earnings EPS Beat Bolsters Investor Confidence Amidst Ongoing Regulatory Challenges Traws Pharma Inc TRAW Q1 2026 Earnings Narrower Net Loss Beats Estimates as Clinical Pipeline Advances LEVI Q1 2026 Earnings EPS Surges Past Estimates on Strong Operational Execution Rigel Pharmaceuticals RIGL Gains Nearly 2 as Stock Tests Key Resistance Near 3124 Waystar Holding Corp WAY Rallies 39 as Momentum Builds Toward Key Resistance Ciena Corporation CIEN Consolidates Near 584 After Slight Pullback Ready Capital RC Edges Lower as Stock Tests Key Support at 172 Petco WOOF Jumps Over 4 as Shares Test Key Resistance at 290 CARE Q1 2026 Earnings EPS Misses Estimates by Over 85 as Stock Rises NextTrip Inc NTRP Q3 2023 Earnings EPS Beats Estimates by a Wide Margin Shares Rally Armata Pharmaceuticals ARMP Q1 2026 Earnings Steep EPS Miss as ClinicalStage Biotech Continues Heavy RD Spending Dole Q1 2026 Earnings EPS Misses Expectations by 34 Shares Edge Lower CLLS Q1 2026 Earnings NarrowerThanExpected Loss Lifts Shares